Evidence map›Paper›PMID 31422337›Full record

ArticleNeuroImage. Clinical2019

Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD.

Nils Richter, Nils Nellessen, Julian Dronse, Kim Dillen, Heidi I L Jacobs, Karl-Josef Langen, Markus Dietlein, Lutz Kracht, Bernd Neumaier, Gereon R Fink and 2 more

Open access · goldAbstract read
In one paragraph

Article in NeuroImage. Clinical, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Nils RichterDepartment of Neurology, University Hospital Cologne, 50937 Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, 52425 Jülich, Germany; Max-Planck-Institute for Metabolism Research, 50937 Cologne, Germany. Electronic address: n.richter@fz-juelich.de.
Nils NellessenDepartment of Neurology, University Hospital Cologne, 50937 Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, 52425 Jülich, Germany.
Julian DronseDepartment of Neurology, University Hospital Cologne, 50937 Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, 52425 Jülich, Germany.
Kim DillenCognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, 52425 Jülich, Germany.
Heidi I L JacobsCognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, 52425 Jülich, Germany; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States of America; The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States of America; Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, the Netherlands.
Karl-Josef LangenMedical Imaging Physics (INM-4), Institute of Neuroscience and Medicine (INM-4), Research Center Jülich, 52425 Jülich, Germany.
Markus DietleinDepartment of Nuclear Medicine, University Hospital Cologne, 50937 Cologne, Germany.
Lutz KrachtMax-Planck-Institute for Metabolism Research, 50937 Cologne, Germany; Department of Nuclear Medicine, University Hospital Cologne, 50937 Cologne, Germany.
Bernd NeumaierInstitute for Radiochemistry and Experimental Molecular Imaging, University Hospital Cologne, 50937 Cologne, Germany; Nuclear Chemistry, Institute of Neuroscience and Medicine (INM-5), Research Center Jülich, 52425 Jülich, Germany.
Gereon R FinkDepartment of Neurology, University Hospital Cologne, 50937 Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, 52425 Jülich, Germany.
Juraj KukoljaCognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, 52425 Jülich, Germany; Department of Neurology and Neurophysiology, Helios University Hospital Wuppertal, 42283 Wuppertal, Germany.
Oezguer A OnurDepartment of Neurology, University Hospital Cologne, 50937 Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, 52425 Jülich, Germany.
Forschungszentrum Jülich · DEHarvard University · USMax Planck Institute for Metabolism Research · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elucidating the relationship between neuronal metabolism and the integrity of the cholinergic system is prerequisite for a profound understanding of cholinergic dysfunction in Alzheimer's disease. The cholinergic system can be investigated specifically using positron emission tomography (PET) with [

Indexed as

Positron-Emission TomographyAcetatesAcetylcholinesteraseAgedAged, 80 and overAlzheimer DiseaseCognitive DysfunctionFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPiperidinesRadiopharmaceuticalsAcetatesAcetylcholinesteraseFluorodeoxyglucose F18N-methyl-4-piperidyl acetatePiperidinesRadiopharmaceuticalsAcetylcholinesteraseAlzheimer's diseaseFDGMP4A

Identifiers

PMID31422337
PMCPMC6706587
OpenAlexW2968156805

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.